newsfilter
← Latest News
GlobeNewswire·

Codiak BioSciences Announces FDA Clearance of IND for exoASO™-STAT6; Patient Dosing Expected 1H 2022

– Codiak's first engineered exosome therapeutic candidate for systemic administration – – Single agent anti-tumor effect observed in preclinical models via macrophage reprogramming – – Phase 1 trial will evaluate safety, tolerability,